No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
DYAI241220C2500
- 0.05
- 0.000.00%
15min DelayClose Dec 20 16:00 ET
0.05High0.05Low
0.05Open0.05Pre Close25 Volume3.23K Open Interest2.50Strike Price125.00Turnover0.00%IV45.71%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma35.00Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Dyadic International Secures Grant for Antibody Development
Express News | Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for Rsv and Malaria Using C1 Platform Technology
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
Dyadic International, Inc. (DYAI) Q3 2024 Earnings Call Transcript Summary
HC Wainwright & Co. Reiterates Buy on Dyadic International, Maintains $6 Price Target
Dyadic International Reports Q3 2024 Growth and Strategic Advances